Chengdu Easton Biopharmaceuticals Adjusts Valuation Amid Changing Financial Metrics and Market Position

Chengdu Easton Biopharmaceuticals Co., Ltd. has recently undergone an adjustment in its evaluation, reflecting changes in its financial metrics and market position. The company's valuation grade has shifted from attractive to fair, with a current P/E ratio of 34 and a Price to Book Value of 2.70. Additionally, the EV to EBIT stands at 35.98, while the EV to EBITDA is recorded at 28.59. The PEG ratio is noted at 2.43, and the dividend yield is currently at 1.37%. In terms of technical trends, there has been a revision in its score, moving from mildly bullish to bullish. However, the MACD indicates a bearish trend on a weekly basis, while the monthly outlook shows a mildly bearish stance. The stock has generated a return of 79.71% over the past year, despite a decline in profits by 4.7%. The company has also demonstrated a solid operating cash flow, reaching its highest at CNY 335.41 million, and a notable decrease in raw material costs by 1.58% year-over-year. Overall, these adjustments highlight the evolving landscape for Chengdu Easton Biopharmaceuticals Co., Ltd. and its positioning within the pharmaceuticals and biotechnology sector. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.